JP2009084284A - カルバペネム系抗生物質、組成物及び調製方法 - Google Patents
カルバペネム系抗生物質、組成物及び調製方法 Download PDFInfo
- Publication number
- JP2009084284A JP2009084284A JP2008268213A JP2008268213A JP2009084284A JP 2009084284 A JP2009084284 A JP 2009084284A JP 2008268213 A JP2008268213 A JP 2008268213A JP 2008268213 A JP2008268213 A JP 2008268213A JP 2009084284 A JP2009084284 A JP 2009084284A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- composition
- pharmaceutically acceptable
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C(C(C1C)N2C(*)=C1SC(C1)CNC1*(C)c1cccc(C(O)=O)c1)C2=O)O Chemical compound CC(C(C(C1C)N2C(*)=C1SC(C1)CNC1*(C)c1cccc(C(O)=O)c1)C2=O)O 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/88—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D499/887—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with a hetero atom or a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
本発明は、式I
本明細書中に用いた「安定形態」という語は、式IIの化合物において示した、ピロリジン窒素原子の位置に生成したカルバメート基を有する化合物を意味する。このようなカルバメートは、式Iの化合物またはその塩、プロドラッグもしくは水和物を炭酸ナトリウムまたは重炭酸ナトリウムといった二酸化炭素源と配合することによって得ることができる。その例を式II及びII−a〜II−gとして示す。
組成物1
化合物I 4.5g
重炭酸ナトリウム 1.0g
組成物2
化合物I 6.7g
炭酸ナトリウム 1.0g
(無水遊離酸36mgに相当)
重炭酸ナトリウム(USP) 8.0mg/ml
塩化ナトリウム(USP) 4.0mg/ml
Claims (21)
- 約3〜6重量部の化合物Iまたはその医薬に許容可能な塩、安定形態、プロドラッグもしくは水和物と約1重量部の重炭酸ナトリウムとを含有することを特徴とする請求項2に記載の組成物。
- 約4.5重量部の式Iの化合物またはその医薬に許容可能な塩、安定形態、プロドラッグもしくは水和物を含有することを特徴とする請求項3に記載の組成物。
- 約3〜6重量部の化合物Iまたはその医薬に許容可能な塩、安定形態、プロドラッグもしくは水和物と約1重量部の炭酸ナトリウムとを含有することを特徴とする請求項2に記載の組成物。
- 約4.5重量部の式Iの化合物またはその医薬に許容可能な塩、安定形態、プロドラッグもしくは水和物を含有することを特徴とする請求項5に記載の組成物。
- 約4〜10重量部の式Iの化合物またはその医薬に許容可能な塩、安定形態、プロドラッグもしくは水和物と1重量部の炭酸ナトリウムとを含有することを特徴とする請求項2に記載の組成物。
- 約6.7重量部の式Iの化合物またはその医薬に許容可能な塩、安定形態、プロドラッグもしくは水和物が1重量部の炭酸ナトリウムと組み合わせられていることを特徴とする請求項7に記載の組成物。
- 約4〜10重量部の式Iの化合物またはその医薬に許容可能な塩、安定形態、プロドラッグもしくは水和物と1重量部の重炭酸ナトリウムとを含有することを特徴とする請求項1に記載の組成物。
- 約6.7重量部の式Iの化合物またはその医薬に許容可能な塩、安定形態、プロドラッグもしくは水和物が1重量部の重炭酸ナトリウムと組み合わせられていることを特徴とする請求項8に記載の組成物。
- デヒドロペプチダーゼ阻害剤も含有することを特徴とする請求項2に記載の組成物。
- デヒドロペプチダーゼ阻害剤がシラスタチンであることを特徴とする請求項11に記載の組成物。
- 二酸化炭素源が二酸化炭素、炭酸ナトリウム及び重炭酸ナトリウムの中から選択されることを特徴とする請求項16に記載の組成物。
- 二酸化炭素源が炭酸ナトリウムまたは重炭酸ナトリウムであることを特徴とする請求項17に記載の組成物。
- 二酸化炭素源を二酸化炭素、炭酸ナトリウム及び重炭酸ナトリウムの中から選択することを特徴とする請求項19に記載の方法。
- 二酸化炭素源を炭酸ナトリウム及び重炭酸ナトリウムの中から選択することを特徴とする請求項20に記載の方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1851896P | 1996-05-28 | 1996-05-28 | |
US60/018,518 | 1996-05-28 | ||
GB9612668.5 | 1996-06-18 | ||
GBGB9612668.5A GB9612668D0 (en) | 1996-06-18 | 1996-06-18 | Carbapenem antibiotic composition and method of preparation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9542800A Division JPH11509871A (ja) | 1996-05-28 | 1997-05-23 | カルバペネム系抗生物質、組成物及び調製方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009084284A true JP2009084284A (ja) | 2009-04-23 |
JP2009084284A5 JP2009084284A5 (ja) | 2011-09-22 |
JP5255983B2 JP5255983B2 (ja) | 2013-08-07 |
Family
ID=26309530
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9542800A Withdrawn JPH11509871A (ja) | 1996-05-28 | 1997-05-23 | カルバペネム系抗生物質、組成物及び調製方法 |
JP2008268213A Expired - Lifetime JP5255983B2 (ja) | 1996-05-28 | 2008-10-17 | カルバペネム系抗生物質、組成物及び調製方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9542800A Withdrawn JPH11509871A (ja) | 1996-05-28 | 1997-05-23 | カルバペネム系抗生物質、組成物及び調製方法 |
Country Status (34)
Country | Link |
---|---|
EP (1) | EP0863901B1 (ja) |
JP (2) | JPH11509871A (ja) |
KR (2) | KR100403497B1 (ja) |
CN (1) | CN1067074C (ja) |
AT (1) | ATE252584T1 (ja) |
AU (1) | AU710102B2 (ja) |
BG (1) | BG63821B1 (ja) |
CA (1) | CA2227994C (ja) |
CO (1) | CO4940412A1 (ja) |
CY (1) | CY2437B1 (ja) |
CZ (1) | CZ296381B6 (ja) |
DE (1) | DE69725696T2 (ja) |
DK (1) | DK0863901T3 (ja) |
DZ (1) | DZ2242A1 (ja) |
EA (1) | EA000534B1 (ja) |
EE (1) | EE04678B1 (ja) |
ES (1) | ES2208907T3 (ja) |
HK (1) | HK1016176A1 (ja) |
HR (1) | HRP970281B1 (ja) |
HU (1) | HU229426B1 (ja) |
ID (1) | ID16974A (ja) |
IL (1) | IL123078A (ja) |
IS (1) | IS2353B (ja) |
MX (1) | MX9800808A (ja) |
NO (1) | NO323815B1 (ja) |
NZ (1) | NZ329649A (ja) |
PL (1) | PL188917B1 (ja) |
PT (1) | PT863901E (ja) |
RS (1) | RS49583B (ja) |
SI (1) | SI0863901T1 (ja) |
SK (1) | SK284359B6 (ja) |
TR (1) | TR199800146T1 (ja) |
TW (1) | TW434014B (ja) |
WO (1) | WO1997045430A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010113492A1 (ja) | 2009-03-31 | 2010-10-07 | 三菱マテリアル株式会社 | 含フッ素n-アルキルスルホニルイミド化合物及びその製造方法、並びにイオン性化合物の製造方法 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2268820A1 (en) * | 1996-10-28 | 1998-05-07 | Merck & Co., Inc. | Stabilized carbapenem antibiotic compositions and method of making |
CN1105719C (zh) * | 1997-06-16 | 2003-04-16 | 麦克公司 | 稳定化碳青霉烯中间体及其合成用途 |
US6180783B1 (en) * | 1997-06-16 | 2001-01-30 | Merck & Co., Inc. | Stabilized carbapenem intermediates and improved process for carbapenem synthesis |
US6504027B1 (en) | 1998-03-02 | 2003-01-07 | Merck & Co., Inc. | Decarboxylation process for synthesizing carbapenem antibiotics |
WO2001032172A1 (en) * | 1999-10-29 | 2001-05-10 | Merck & Co., Inc. | Process for formulation of carbapenem antibiotic compositions |
AR035728A1 (es) | 2001-01-16 | 2004-07-07 | Merck & Co Inc | Proceso perfeccionado para la sintesis de carbapenem |
CN101357918B (zh) * | 2007-06-22 | 2011-05-18 | 山东轩竹医药科技有限公司 | 含有异硫脲基巯基吡咯烷的培南衍生物 |
CN101367815B (zh) * | 2007-06-28 | 2012-07-04 | 山东轩竹医药科技有限公司 | 六元环甲酰胺取代的巯基吡咯烷碳青霉烯化合物 |
JPWO2009075309A1 (ja) | 2007-12-12 | 2011-04-28 | 大日本住友製薬株式会社 | 製剤組成物 |
CN101550138B (zh) * | 2008-04-03 | 2011-05-18 | 山东轩竹医药科技有限公司 | 巯基氮杂环烷酰胺醇取代的培南衍生物 |
EP2505190A1 (en) * | 2008-06-11 | 2012-10-03 | Ranbaxy Laboratories Limited | Polymorphic forms of ertapenem monosodium salt and process for it's preparation |
CN102803649A (zh) | 2009-06-25 | 2012-11-28 | 国际壳牌研究有限公司 | 注水系统和方法 |
WO2012047832A2 (en) | 2010-10-07 | 2012-04-12 | Shell Oil Company | Process for the production of alcohols from biomass |
EP2635712B1 (en) | 2010-11-05 | 2014-07-02 | Shell Oil Company | Treating biomass to produce materials useful for biofuels |
WO2012088108A1 (en) | 2010-12-20 | 2012-06-28 | Shell Oil Company | Process for the production of alcohols from biomass |
CN103987851B (zh) | 2011-12-15 | 2016-06-01 | 国际壳牌研究有限公司 | 处理来自乙醇生产的副产物的方法 |
WO2013173563A1 (en) | 2012-05-17 | 2013-11-21 | Shell Oil Company | Process for producing volatile organic compounds from biomass material |
CN103860485A (zh) * | 2012-12-18 | 2014-06-18 | 深圳市海滨制药有限公司 | 一种厄他培南钠冻干制剂及其制备方法 |
US20150299739A1 (en) | 2014-04-17 | 2015-10-22 | Shell Oil Company | Processes for producing fermentation products |
WO2016025678A1 (en) | 2014-08-14 | 2016-02-18 | Shell Oil Company | Process for preparing furfural from biomass |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5973518A (ja) * | 1982-09-10 | 1984-04-25 | グラクソ・グル−プ・リミテツド | 薬学的組成物 |
JPH0625244A (ja) * | 1992-03-26 | 1994-02-01 | Zeneca Ltd | カルバペネム、抗菌作用を有する医薬調剤、該化合物を製造するための方法および中間体 |
JPH06506704A (ja) * | 1992-02-04 | 1994-07-28 | ゼネカ リミテッド | 抗生物質組成物 |
-
1997
- 1997-05-21 HR HR970281A patent/HRP970281B1/xx not_active IP Right Cessation
- 1997-05-23 DE DE69725696T patent/DE69725696T2/de not_active Expired - Lifetime
- 1997-05-23 SK SK109-98A patent/SK284359B6/sk not_active IP Right Cessation
- 1997-05-23 AU AU30775/97A patent/AU710102B2/en not_active Expired
- 1997-05-23 ES ES97925725T patent/ES2208907T3/es not_active Expired - Lifetime
- 1997-05-23 PL PL97324746A patent/PL188917B1/pl unknown
- 1997-05-23 KR KR10-2001-7008925A patent/KR100403497B1/ko not_active IP Right Cessation
- 1997-05-23 AT AT97925725T patent/ATE252584T1/de active
- 1997-05-23 EE EE9800022A patent/EE04678B1/xx unknown
- 1997-05-23 CZ CZ0025398A patent/CZ296381B6/cs not_active IP Right Cessation
- 1997-05-23 WO PCT/US1997/008831 patent/WO1997045430A1/en active IP Right Grant
- 1997-05-23 HU HU9901567A patent/HU229426B1/hu unknown
- 1997-05-23 TR TR1998/00146T patent/TR199800146T1/xx unknown
- 1997-05-23 RS YUP-41/98A patent/RS49583B/sr unknown
- 1997-05-23 MX MX9800808A patent/MX9800808A/es active IP Right Grant
- 1997-05-23 IL IL12307897A patent/IL123078A/en not_active IP Right Cessation
- 1997-05-23 NZ NZ329649A patent/NZ329649A/en not_active IP Right Cessation
- 1997-05-23 DK DK97925725T patent/DK0863901T3/da active
- 1997-05-23 KR KR1019980700717A patent/KR100344479B1/ko not_active IP Right Cessation
- 1997-05-23 CA CA002227994A patent/CA2227994C/en not_active Expired - Lifetime
- 1997-05-23 SI SI9730603T patent/SI0863901T1/xx unknown
- 1997-05-23 JP JP9542800A patent/JPH11509871A/ja not_active Withdrawn
- 1997-05-23 PT PT97925725T patent/PT863901E/pt unknown
- 1997-05-23 CN CN97190911A patent/CN1067074C/zh not_active Expired - Lifetime
- 1997-05-23 EA EA199800180A patent/EA000534B1/ru not_active IP Right Cessation
- 1997-05-23 EP EP97925725A patent/EP0863901B1/en not_active Expired - Lifetime
- 1997-05-26 CO CO97028781A patent/CO4940412A1/es unknown
- 1997-05-26 ID IDP971736A patent/ID16974A/id unknown
- 1997-05-27 DZ DZ970091A patent/DZ2242A1/fr active
- 1997-05-28 TW TW086107254A patent/TW434014B/zh not_active IP Right Cessation
-
1998
- 1998-01-27 IS IS4663A patent/IS2353B/is unknown
- 1998-01-28 NO NO19980380A patent/NO323815B1/no not_active IP Right Cessation
- 1998-02-24 BG BG102273A patent/BG63821B1/bg unknown
-
1999
- 1999-03-29 HK HK99101281A patent/HK1016176A1/xx not_active IP Right Cessation
-
2004
- 2004-04-26 CY CY0400030A patent/CY2437B1/xx unknown
-
2008
- 2008-10-17 JP JP2008268213A patent/JP5255983B2/ja not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5973518A (ja) * | 1982-09-10 | 1984-04-25 | グラクソ・グル−プ・リミテツド | 薬学的組成物 |
JPH06506704A (ja) * | 1992-02-04 | 1994-07-28 | ゼネカ リミテッド | 抗生物質組成物 |
JPH0625244A (ja) * | 1992-03-26 | 1994-02-01 | Zeneca Ltd | カルバペネム、抗菌作用を有する医薬調剤、該化合物を製造するための方法および中間体 |
Non-Patent Citations (2)
Title |
---|
JPN6012007010; Chem. Pharm. Bull. Vol.41, No.11, 1993, pp.1998-2002 * |
JPN6012007011; Chem. Pharm. Bull. Vol.43, No.4, 1995, pp.689-692 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010113492A1 (ja) | 2009-03-31 | 2010-10-07 | 三菱マテリアル株式会社 | 含フッ素n-アルキルスルホニルイミド化合物及びその製造方法、並びにイオン性化合物の製造方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5255983B2 (ja) | カルバペネム系抗生物質、組成物及び調製方法 | |
US5952323A (en) | Carbapenem antibiotic | |
EP1207881B1 (en) | Pharmaceutical agent comprising a benzamide derivative as active ingredient | |
CA2949328C (en) | Low substituted polymyxins and compositions thereof | |
EP0178911B1 (en) | Composition containing a penem or carbapenem antibiotic | |
MXPA01006698A (es) | Solucion de las al monosodica de la n-[o-(p-pivaloiloxibencensulfonilamino)benzoil]glilicina tetrahidratada y producto farmaceutico de la misma. | |
KR930001830B1 (ko) | 항균성 동결건조 제제 | |
EP0238207B1 (en) | Bactericidal mixtures | |
JP2000508343A (ja) | 安定化されたカルバペネム抗生物質組成物及びその製造方法 | |
AU2001294004B2 (en) | Pharmaceutical compositions containing oxapenem-3-carboxylic acids | |
US20230399355A1 (en) | Antimicrobial compounds, compositions, and uses thereof | |
WO2014164526A1 (en) | Oxamazin antibiotics | |
BR9702231B1 (pt) | composição farmacêutica, composto, e, processo para estabilizar um carbapenem | |
GB2369358A (en) | Oxapenems and pharmaceutical compositions thereof | |
JPS6191191A (ja) | 抗菌性7β‐複素環式セフエム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110810 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120508 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120511 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120813 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121030 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130123 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130128 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130221 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20130223 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130226 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130312 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130416 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130422 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160426 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |